Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 6, 2014, Pages 238-246

  Eriksson, Sophie E ^a   Elgström, Erika ^a   Bäck, Tom ^b   Ohlsson, Tomas ^a   Jensen, Holger ^c   Nilsson, Rune ^a   Lindegren, Sture ^b   Tennvall, Jan ^a,d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c University of Copenhagen   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

astatine 211; lutetium 177; radioimmunotherapy; targeted alpha therapy

Indexed keywords

CYCLOSPORIN A; HALOGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR96 AT 211; MONOCLONAL ANTIBODY BR96 LU 177; MONOCLONAL ANTIBODY BR96 TETRAXETAN LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ASTATINE; BR96 MONOCLONAL ANTIBODY; LUTETIUM; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW TOXICITY; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; ERYTHROCYTE COUNT; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LEUKOCYTE COUNT; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; THROMBOCYTE COUNT; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ALPHA RADIATION; ANIMAL; COLONIC NEOPLASMS; DISEASE MODEL; HUMAN; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LUTETIUM; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS;

EID: 84904631605     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1625     Document Type: Article

References (31)

1. Kassis AI. Therapeutic radionuclides: Biophysical and radiobiologic principles. Semin Nucl Med 2008;38:358.
2. Forrer F, Oechslin-Oberholzer C, Campana B, et al. Is there need for radioimmunotherapy? Results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging 2012;56:544.
3. Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostatespecific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010;116(4 Suppl):1075.
4. de Jong GM, Boerman OC, Heskamp S, et al. Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model. Br J Surg 2009;96:314.
5. Aarts F, Hendriks T, Boerman OC, et al. Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin. Cancer Biother Radiopharm 2008;23:301.
6. Back T, Andersson H, Divgi CR, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med 2005;46:2061.
7. Palm S, Back T, Claesson I, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 2007; 69:572.
8. Elgqvist J, Andersson H, Back T, et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342.
9. Eriksson SE, Ohlsson T, Nilsson R, et al. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother Radiopharm 2012;27:134.
10. Eriksson SE, Back T, Elgstrom E, et al. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. EJNMMI Res 2013;3:23.
11. Eriksson SE, Ohlsson T, Nilsson R, et al. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother Radiopharm 2012;27:175.
12. Hellstrom I, Garrigues HJ, Garrigues U, et al. Highly tumorreactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990;50:2183.
13. Martensson L, Nilsson R, Ohlsson T, et al. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: Evaluation of toxicity, therapeutic effect, and tumor model. Cancer 2010;116(4 Suppl):1043.
14. Lindegren S, Andersson H, Back T, et al. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol 2001;28:33.
15. Lindegren S, Frost S, Back T, et al. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl- 3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med 2008;49:1537.
16. Dearling JL, Flynn AA, Qureshi U, et al. Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: Influence of tumor size and location within host organ on antibody uptake. Nucl Med Biol 2009;36:883.
17. Pedley RB, Boden J, Keep PA, et al. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med 1987;13:197.
18. Fidarova EF, El-Emir E, Boxer GM, et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: Implications for radioimmunotherapy. Clin Cancer Res 2008;14: 2639.
19. Li XF, Carlin S, Urano M, et al. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007;67:7646.
20. Polzer B, Klein CA. Metastasis awakening: The challenges of targeting minimal residual cancer. Nat Med 2013;19: 274.
21. Elgqvist J, Andersson H, Haglund E, et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm 2009;24:509.
22. Elgstrom E, Eriksson SE, Ohlsson TG, et al. Pattern of antigen expression in metastases after radioimmunotherapy of a syngeneic rat colon carcinoma utilizing the BR96 antibody. Exp Hematol Oncol 2012;1:34.
23. de Jong M, Breeman WA, Valkema R, et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S.
24. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu- DOTATATE: Which is a better therapy option? Eur J Nucl Med Mol Imaging 2011;38:1788.
25. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]- TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100.
26. Li Y, Song E, Abbas Rizvi SM, et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeledmultiple targeted alpha radioimmunoconjugates. Clin Cancer Res 2009;15:865.
27. Song H, Sgouros G. Radioimmunotherapy of solid tumors: Searching for the right target. Curr Drug Deliv 2011;8:26.
28. Tomblyn MB, Katin MJ, Wallner PE. The new golden era for radioimmunotherapy: Not just for lymphomas anymore. Cancer Control 2013;20:60.
29. Hanscheid H, Reiners C, Goulko G, et al. Facing the nuclear threat: Thyroid blocking revisited. J Clin Endocrinol Metab 2011;96:3511.
30. Frost SH, Back T, Chouin N, et al. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal alpharadioimmunotherapy. Cancer Biother Radiopharm 2011; 26:727.
31. McLendon RE, Archer GE, Larsen RH, et al. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys 1999;45:491.